or Try an Advanced Search...

    Technical Analysis for TARA - ArTara Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 2.47 -1.59% -0.04
    TARA closed down 1.59 percent on Friday, November 1, 2024, on 1.41 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical TARA trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Earnings Movers Other 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Upper Bollinger Band Walk Strength -1.59%
    Wide Bands Range Expansion -1.59%
    Above Upper BB Strength -1.59%
    Overbought Stochastic Strength -1.59%
    Older End-of-Day Signals for TARA ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 19 hours ago
    Down 5% about 21 hours ago
    Down 3% about 21 hours ago
    Down 2 % about 22 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TARA Chart by TradingView
    Basic chart:

    Profile

    ArTara Therapeutics, Inc., a clinical-stage company, develops product candidates for patients suffering from rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The company's lead program is TARA-002, a cellular therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. ArTara Therapeutics, Inc. is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Rare Diseases Gastrointestinal Vitamins Chloride Lipid Liver Disease Hepatology Metabolic Disorders Choline Connective Tissue Cholinergics Treatment Of Rare Diseases

    Is TARA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 21 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
    Sep 9 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
    Sep 9 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
    Sep 3 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 8 Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
    Aug 6 Protara Therapeutics GAAP EPS of -$0.45
    Aug 6 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
    Jun 24 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    May 21 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
    May 2 Protara Therapeutics GAAP EPS of -$0.97
    See more TARA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.24
    52 Week Low 1.04
    Average Volume 171,814
    200-Day Moving Average 2.66
    50-Day Moving Average 1.93
    20-Day Moving Average 1.99
    10-Day Moving Average 2.21
    Average True Range 0.18
    RSI (14) 71.01
    ADX 33.71
    +DI 31.37
    -DI 7.62
    Chandelier Exit (Long, 3 ATRs) 2.00
    Chandelier Exit (Short, 3 ATRs) 2.14
    Upper Bollinger Bands 2.55
    Lower Bollinger Band 1.43
    Percent B (%b) 0.93
    BandWidth 56.00
    MACD Line 0.15
    MACD Signal Line 0.08
    MACD Histogram 0.0694
    Fundamentals Value
    Market Cap 28.07 Million
    Num Shares 11.4 Million
    EPS -6.13
    Price-to-Earnings (P/E) Ratio -0.40
    Price-to-Sales 0.00
    Price-to-Book 0.45
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.79
    Resistance 3 (R3) 2.78 2.66 2.73
    Resistance 2 (R2) 2.66 2.58 2.67 2.71
    Resistance 1 (R1) 2.57 2.53 2.51 2.58 2.70
    Pivot Point 2.45 2.45 2.43 2.46 2.45
    Support 1 (S1) 2.36 2.37 2.30 2.37 2.24
    Support 2 (S2) 2.24 2.32 2.25 2.23
    Support 3 (S3) 2.15 2.24 2.21
    Support 4 (S4) 2.16